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Atrial fibrillation (AF) is associated with major adverse car-
diovascular and cerebral events, including stroke. In order
to prevent stroke, oral anticoagulation (OAC) therapy is
prescribed guided by risk-stratification scores, nowadays
the CHA2DS2-VASc score [1]. For more than 50 years
vitamin K antagonists (VKA) have had a central role in
stroke prevention in patients with AF. Most important lim-
itations of VKAs, however, include the need for frequent
monitoring of the international normalised ratio (INR) and
dosing changes. Despite repeated assessment of the INR
and dosing changes, it remains difficult to achieve thera-
peutic ranges in a substantial number of patients due to
drug and food interactions, poor adherence or other, yet
unknown, factors [2]. Non vitamin K oral anticoagulation
drugs (NOAC) are now available as an alternative to VKA
[3–6]. Many AF patients who qualify for OAC treatment
are candidates for these drugs. However, despite fast adop-
tion of these new drugs in other countries, the prescription
rate in the Netherlands is still lower than expected.
In this issue of the Netherlands Heart Journal, Ten Cate
et al. describe the use of NOACs in the Netherlands in
order to provide information on the prescription behaviour
of OACs in patients with AF [7]. Data are shown from the
Global Anticoagulant Registry in the FIELD-Atrial Fibrilla-
tion (GARFIELD-AF), a worldwide multicentre registry on
anticoagulants use in patients with AF. A total of 41,677
patients with new-onset AF (<6 weeks) with at least one
additional risk factor for stroke were included in 35 coun-
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tries; 929 of them were enrolled in 16 Dutch centres. Pa-
tients were included in three different cohorts during three
successive years of inclusion. One finding of interest of
this registry is between 4.4 % and 7.3 % did not use any
kind of antithrombotic drugs and a comparable number
of patients only used antiplatelet therapy. Further, they
observed a gradual but small increase in the NOAC pre-
scription rate in the successive cohorts. In the first cohort
(December 2009–October 2011) none of the patients used
a NOAC because none of these drugs had been approved
in the Netherlands at that time. In the third and last cohort
(inclusion June 2013–June 2014), however, 14.5 % of the
patients used a NOAC, which is higher than the NOAC pre-
scription rate in the second cohort (2.7 %, inclusion October
2011 and June 2013). However, this number is still signifi-
cantly lower compared with other parts of the world (40 %
in the third cohort). The authors’ explanation for the cur-
rent low NOAC prescription rate in the Netherlands is the
presence and structure of well-organised specialised clinics
for VKA monitoring in our country. These clinics facili-
tate INR monitoring and dosing changes. Other countries
rarely have a structure in which these tasks are facilitated.
Further, three of these specialised clinics enrolled patients
for the GARFIELD, which may also have contributed to
the relatively high proportion of patients using VKA and
the slow uptake of NOACs in this registry.
The authors are congratulated on sharing these data with
us. This gives an indication of the prescription of OAC
in the Netherlands until June 2014. It highlights two hur-
dles we encounter when prescribing OACs in patients with
AF. First, a dilemma in starting OAC is always to balance
efficacy of stroke prevention and safety in terms of side ef-
fects – especially major bleeding. Prescription of OAC in
daily practice is not always consistent with current guide-
lines, as has been demonstrated by data from the present
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study and which approves data from the Euro Heart Sur-
vey and the EURObservational Research Programme [8,
9]. Also other data confirm the inadequate prescription of
OAC in patients at risk for stroke. An analysis of the first
10,000 patients from the GLObal RegIstry on long-term
oral Anti-thrombotic treatment in patients with Atrial Fib-
rillation (GLORIA-AF) showed that 17.6 % of all patients
with a CHA2DS2-VASc score ≥2 did not use adequate an-
tithrombotic therapy [10]. These numbers, however, greatly
differed per region, from 8.1 % in Europe up to 37.6 % in
Asia. The other way around, remarkably the same registry
showed that 38.7 % of the patients with a CHA2DS2-VASc
score of 0 did receive antithrombotic therapy [11].
A second dilemma highlighted by the authors is whether
or not to start with a NOAC instead of the prescribing the
well-known VKAs. Since the first NOAC approval of the
direct thrombin inhibitor dabigatran for the Dutch market
in 2011, three other NOACs, direct factor Xa inhibitors (ri-
varoxaban, apixaban and edoxaban), have been introduced.
Large phase III clinical trials have all shown NOACs to be
non-inferior, sometimes even superior, in terms of preven-
tion of stroke and systemic embolic events in patients with
AF and comparable rates of major bleeding [3–6]. In addi-
tion, all NOAC trials showed a 50 % reduction in intracra-
nial haemorrhage rate compared with VKAs. Meta-anal-
ysis of these trials confirm the non-inferiority of NOACs
and sometimes even suggest a superior effect in stroke pre-
vention and systemic embolism [12]. Thus, the available
data now show that NOACs are safe and effective drugs.
In addition, their pharmacological properties allow NOACs
to be given at fixed doses without the need for laboratory
monitoring except for renal function and few drug interac-
tions exist. Despite these data, a NOAC prescription rate
of 7.4 % in the Netherlands was observed in 2015, which is
second-lowest rate in Europe. Countries such as Germany,
Greece and Switzerland have rates of over 40 %.
How can the low prescription rate of NOACs in our, of-
ten open-minded country, be explained? It may relate to
the previously mentioned specialised clinics for VKA man-
agement. In other countries, prescribing VKA increases
the workload for physicians, in contrast to the Netherlands.
Here, institution of NOACs causes an increased and new,
yet unfamiliar workload. Another possible explanation is
the inability to monitor the anticoagulation effect, which
makes the prescribing physician nervous and reluctant, es-
pecially in patients with an expected poor drug adherence.
Lack of an antidote may be another reason not to prescribe
NOACs. Although its relevance can be discussed, this is-
sue is now partly resolved since the first NOAC antidote for
dabigatran has been approved [13]. However, perhaps the
biggest hurdle to take is getting used to these new drugs.
It often takes time to become familiar with new drugs and
treatment strategies. Data from randomised clinical trials
are obtained in a controlled environment with highly mo-
tivated patients, whereas ‘real world’ data are needed to
confirm efficacy and safety and persuade the prescribing
physician to change. Several registries now all demonstrate
favourable data. The Xarelto for Prevention of Stroke in
Patients with Atrial Fibrillation (XANTUS) trial, an inter-
national prospective observational study in 311 sites in Eu-
rope, Israel and Canada, included 6785 consecutive patients
in whom rivaroxaban was initiated and followed the patients
for almost 1 year [14]. The rate per 100 patients-years of
stroke, major bleeding and mortality was 0.7, 2.1 and 1.9,
respectively, which compares favourably with data of the
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET
AF) [5]. These favourable ‘real world’ data were confirmed
by other registries [15, 16].
NOACs are non-inferior and in some cases superior in
terms of effectiveness and safety compared with VKA in
patients with non-valvular AF. Real world data are becom-
ing more and more available and support that NOACs are
safe, effective and easy to use. Despite that, the prescription
rate of NOACs in the Netherlands is still low, especially
compared with other countries in Europe and the rest of
the world. The luxury of having well-organised specialised
clinics for VKA management may be one hurdle, as well as
getting used to the new treatment options. However, nowa-
days we see an increase in NOAC use, which persuades us
that in the end NOACs will win the race.
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